Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer immunotherapy cocktail shows promise but trial halted early

NCT ID NCT04832854

Terminated Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested two immunotherapy drugs (tiragolumab and atezolizumab) with or without chemotherapy in 50 people with early-stage non-small cell lung cancer that could be surgically removed. The goal was to see if the treatment shrank tumors before surgery and prevented return after. The study was terminated early, so results are limited, but researchers looked at surgical safety and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tiragolumab and atezolizumab (immunotherapy drugs) with or without platinum-based chemotherapy
What this could lead to
If successful, this combination could improve tumor shrinkage before surgery and reduce recurrence after surgery for lung cancer patients.
What could go wrong
The trial was terminated early, so data is limited. Immunotherapy can cause immune-related side effects, and adding chemo increases toxicity. Results may not apply to all lung cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

  • City of Hope Cancer Center

    Duarte, California, 91010, United States

  • Columbia University

    New York, New York, 10032-3725, United States

  • Complejo Hospitalario Universitario A Coruña (CHUAC)

    A Coruña, 15006, Spain

  • Corporacio Sanitaria Parc Tauli

    Sabadell, Barcelona, 08208, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Puerta de Hierro

    Majadahonda, Madrid, 28222, Spain

  • ICO L'Hospitalet

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • Kantonsspital Baden

    Baden, 5404, Switzerland

  • Kantonsspital Graubünden Medizin Onkologie

    Chur, 7000, Switzerland

  • Kantonsspital St. Gallen

    Sankt Gallen, 9007, Switzerland

  • Kantonsspital Winterthur

    Winterthur, 8401, Switzerland

  • NYU Cancer Center

    New York, New York, 10016, United States

  • Peter Maccallum Cancer Institute

    Melbourne, Victoria, 3000, Australia

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • St. Vincent's Hospital

    Gyeonggi-do, 16247, South Korea

  • Sunshine Coast University Hospital

    Birtinya, Queensland, 4575, Australia

  • University of Southern California

    Los Angeles, California, 90033, United States

  • UniversitätsSpital Zürich

    Zurich, 8091, Switzerland

  • Vall d?Hebron Institute of Oncology (VHIO), Barcelona

    Barcelona, 08035, Spain

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Winthrop Univ Hospital

    Mineola, New York, 11501, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.